Prima in high-level licensing talks
18 February, 2002 by Tanya HollisPrima BioMed has commenced preliminary talks with several major drug companies over potential licensing options for its new anti-inflammatory compound,VIB 153.
Prima BioMed has commenced preliminary talks with several major drug companies over potential licensing options for its new anti-inflammatory compound,VIB 153.
The Data-Ready Foundation for an AI-Powered Healthcare Future
Innovating chemical dosing & dilution in aged care
A shift in clinical practice: optimal antibiotics for golden staph bloodstream infections
The rise of non-clinical, community-led safe spaces: how lived experience is reshaping suicide prevention
Mandatory VR violence training for nursing students